Loviride

From WikiMD's WELLNESSPEDIA

Loviride is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was primarily developed for the treatment of HIV and AIDS. It is a synthetic compound that inhibits the replication of HIV-1, the most common strain of the virus. Loviride was developed by Janssen Pharmaceutica, a Belgium-based pharmaceutical company.

History[edit]

Loviride was first synthesized in the early 1990s as part of a concerted effort to develop effective treatments for HIV and AIDS. It was one of the first NNRTIs to be developed, following the discovery of the reverse transcriptase enzyme and its role in the replication of HIV.

Mechanism of Action[edit]

As an NNRTI, Loviride works by binding to the reverse transcriptase enzyme, a key component in the replication of HIV. By binding to this enzyme, Loviride prevents the virus from transcribing its RNA into DNA, a necessary step in the replication process. This effectively halts the spread of the virus within the body.

Clinical Trials and Efficacy[edit]

Loviride has undergone several clinical trials to assess its efficacy and safety. In these trials, it has generally been found to be well-tolerated and effective at reducing viral load in patients with HIV. However, it is less potent than some other NNRTIs, and its use has been largely superseded by newer drugs in this class.

Side Effects and Contraindications[edit]

Common side effects of Loviride include nausea, vomiting, diarrhea, and rash. It may also cause changes in liver enzymes, which can lead to hepatotoxicity in some patients. Loviride is contraindicated in patients with severe liver disease.

Current Status[edit]

While Loviride was once a promising treatment for HIV and AIDS, it is no longer widely used due to the development of more effective and better-tolerated NNRTIs. However, it remains an important part of the history of HIV treatment and has contributed to our understanding of the virus and how to combat it.


This HIV related article is a stub. You can help WikiMD by expanding it.

This article is a stub related to pharmacology. You can help WikiMD by expanding it!


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Loviride&oldid=6305081"